Understanding how EBV-infected cells behave in non-Hodgkin lymphomas
Defining and exploiting EBV-infected cell heterogeneity in non-Hodgkin lymphomas
This study is looking at how the Epstein-Barr virus affects certain types of blood cancers called non-Hodgkin lymphomas by examining the different ways infected cells behave, which could help find better treatments for patients like you.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10898747 on NIH RePORTER |
What this research studies
This research investigates the role of Epstein-Barr virus (EBV) in the development of non-Hodgkin lymphomas, particularly focusing on the diversity of infected B cells. By using advanced techniques like single-cell RNA sequencing, the study aims to uncover the different behaviors and characteristics of individual EBV-infected cells. This approach will help researchers understand how these cells contribute to cancer progression and may lead to new therapeutic strategies. Patients may benefit from insights gained about their specific cancer types and potential treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-Hodgkin lymphomas, particularly those associated with Epstein-Barr virus infection.
Not a fit: Patients with non-Hodgkin lymphomas not associated with EBV or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatments for patients with non-Hodgkin lymphomas associated with EBV.
How similar studies have performed: Previous research has shown promising results in understanding EBV's role in lymphomas, but this specific approach using single-cell analysis is relatively novel.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Luftig, Micah a. — Duke University
- Study coordinator: Luftig, Micah a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.